Bendigo Health

bendigohealth.org.au

With more than 3500 staff and covering an area a quarter of the size of Victoria, Bendigo Health Care Group (commonly known as Bendigo Health) is an expanding regional health service offering the advantages of city life combined with the beauty and freedom that comes from living in a regional area. Bendigo Health, around 665 bed service*, treated almost 42,000 inpatients, triaged more than 50,000 emergency attendees and welcomed more than 1,400 new born babies in the reporting period July 1, 2015 to June 30, 2016.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

news image

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More

Industrial Impact

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

news image

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

Industry Outlook

EXPANDING DIAGNOSTICS BUSINESS: SCHOTT SIGNS AGREEMENT TO ACQUIRE APPLIED MICROARRAYS INC.

Applied Microarrays Inc. | September 30, 2021

news image

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through th...

Read More

ENTERPRISE THERAPEUTICS NABS NOVARTIS VC EXEC AS NEW CMO

FierceBiotech | February 10, 2020

news image

Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....

Read More
news image

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More
news image

Industrial Impact

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

news image

Industry Outlook

EXPANDING DIAGNOSTICS BUSINESS: SCHOTT SIGNS AGREEMENT TO ACQUIRE APPLIED MICROARRAYS INC.

Applied Microarrays Inc. | September 30, 2021

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through th...

Read More
news image

ENTERPRISE THERAPEUTICS NABS NOVARTIS VC EXEC AS NEW CMO

FierceBiotech | February 10, 2020

Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us